November 2016 Awareness Night Sexual Health and Prostate Cancer Dr. Andrew G. Matthew, PhD., C.Psych Assistant Professor, Department of Surgery Assistant Professor, Department of Psychiatry Faculty of Medicine, University of Toronto Senior staff Psychologist, Member of the Department of Psychosocial Oncology and Palliative Care Co-Lead, Genito-Urinary Survivorship Program at the Princess Margaret Cancer Centre CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation 48:45 minutes
From ZEROHour Newsletter: January 2017 The newly released “2017 Cancer Facts and Figures” report shows the negative impact of the USPSTF recommendation against the PSA test. Read the Newsletter.
In a small study in 2006, University of California researchers found that drinking a daily 227ml glass of pomegranate juice significantly slowed the progress of prostate cancer — it’s thought urolithins block cancer cell growth. Now a U.S. trial involving 30 patients is looking at whether supplements containing the fruit’s extract can prevent prostate cancer spreading. Read the article here.
A Pilot Study to Evaluate the Role of Magnetic Resonance Imaging for Prostate Cancer Screening in the General Population
A pilot study at the Sunnybrook Health Sciences Centre determined the feasibility of using multiparametric prostate magnetic resonance imaging as the primary screening test for prostate cancer. Initial results showed that prostate magnetic resonance imaging was better to predict prostate cancer than prostate specific antigen in an unselected sample of the general population. Read the article here.
Many men who are told their surgery for prostate cancer has been a success later discover that this is not the case. The level of a protein in their blood, called prostate specific antigen, PSA, begins to rise signalling they still have prostate cells in their body even though they were told the entire prostate had been removed. There has been long standing debate about how best to predict who will fail after surgery. The current debate focuses on the value of pathologists examining the excised prostate and trying to detect, under the microscope, whether tumour cells have invaded the
Scientists at Swansea University say they have made a breakthrough which could revolutionise prostate cancer treatment. Researchers at the university’s School of Medicine have developed a way of shrinking cancer cells using a harmless strain of salmonella bacteria. Read the article here.
Because PSA is secreted both by normal cells and cancer cells, its levels could be high for other reasons and not necessarily cancer: age, an inflammation of the prostate gland, or even a bicycle ride. But most often when doctors receive a high reading, they send their patients to do a biopsy, just to be on the safe side. Cleveland Diagnostics is developing a technology and test kit that can identify the PSA that specifically comes from cancer cells. Read the article here.
Howard Wolinsky, a journalist based in the Chicago area, was diagnosed with early prostate cancer in 2010. After over 5 years of active surveillance, he describes his continuing quest to make the best — and most informed — decision about his care. Read the article here.
The introduction of multiparametric MRI (mpMRI) has improved the diagnosis and risk stratiﬁcation of intermediate and high-risk prostate cancer. In addition to diagnosis, mpMRI has increasingly become a useful tool for monitoring the prostate cancer risk of patients on active surveillance (AS) programmes. Long-term data indicates that there is no oncological beneﬁt for AS programmes for patients diagnosed with intermediate risk prostate cancer. Further, there is increasing evidence that PI-RADS 4 lesion on mpMRI correlates with intermediate and high-risk prostate cancer. Read the article here.